CN112107548A - 一种含有尼替西农的药物组合物及其制备方法 - Google Patents
一种含有尼替西农的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN112107548A CN112107548A CN202011193048.0A CN202011193048A CN112107548A CN 112107548 A CN112107548 A CN 112107548A CN 202011193048 A CN202011193048 A CN 202011193048A CN 112107548 A CN112107548 A CN 112107548A
- Authority
- CN
- China
- Prior art keywords
- acid
- composition
- nitisinone
- granulation
- glidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OUBCNLGXQFSTLU-UHFFFAOYSA-N nitisinone Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1C(=O)C1C(=O)CCCC1=O OUBCNLGXQFSTLU-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960001721 nitisinone Drugs 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 16
- 238000000227 grinding Methods 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000000945 filler Substances 0.000 claims abstract description 7
- 239000003381 stabilizer Substances 0.000 claims abstract description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000015165 citric acid Nutrition 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 238000003801 milling Methods 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 235000011087 fumaric acid Nutrition 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 150000003839 salts Chemical group 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical group 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 229910002012 Aerosil® Inorganic materials 0.000 claims 1
- 229920005682 EO-PO block copolymer Polymers 0.000 claims 1
- 238000009477 fluid bed granulation Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 abstract description 12
- 239000002775 capsule Substances 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 229960004106 citric acid Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 241000220223 Fragaria Species 0.000 description 4
- 235000016623 Fragaria vesca Nutrition 0.000 description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006070 nanosuspension Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 201000011296 tyrosinemia Diseases 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007613 slurry method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种含有尼替西农的药物组合物,原材料包括尼替西农、表面稳定剂、助流剂、PH调节剂、以及填充剂,采用湿法介质研磨方法制备该药物组合物。本发明的优点在于,改善了药物的口服生物利用度;该组合物可在常温下保持稳定,可显著降低药品的储存和流通成本;采用本发明制备出的颗粒可进一步制得药物颗粒剂、胶囊剂、片剂等药物剂型,制备方法简单、成本适宜,适用于工业化大规模生产。
Description
技术领域
本发明属于药物技术领域,具体为一种含有尼替西农的药物组合物及其制备方法。
背景技术
尼替西农是一种合成的4-羟苯丙酮酸双氧酶可逆抑制剂,主要适用于罕见儿科Ⅰ型遗传性酪氨酸血症(HT-1)的治疗。尼替西农几乎不溶于水,不溶于盐酸,在水和盐酸中溶解度低,分别为5×10-3mg/ml和<1×10-3mg/ml,其较低的溶解性影响了其口服生物利用度。目前尼替西农的上市剂型有片剂、胶囊以及口服混悬液,尼替西农制备成制剂后稳定性差,且现有技术的尼替西农药物口服生物利用度也并不理想。
发明内容
为了解决现有技术中的尼替西农药物口服生物利用率较低、稳定性差的的问题,本发明提供了一种含有尼替西农的药物组合物及其制备方法,实现的目的为提高其口服生物利用度及稳定性,提高患者的顺应性,具有一定的临床价值。
为了实现上述目的,本发明提供以下技术方案:本发明提供的一种含有尼替西农的药物组合物,该组合物包括尼替西农、表面稳定剂、助流剂、PH调节剂、以及填充剂,各原材料占组合物的重量百分比分别为:尼替西农0.1%-10%,表面稳定剂0.1%-5%,助流剂0%-1%,PH调节剂0%-5%,填充剂70-95%。
进一步的,表面稳定剂是羟丙基纤维素、羟丙甲基纤维素、聚乙烯吡咯烷酮、环氧乙烷和环氧丙烷的嵌段共聚物、磺基琥珀酸二辛酯钠和十二烷基硫酸钠、泊洛沙姆、聚乙二醇维生素E琥珀酸酯的一种或一种以上。
进一步的,所述助流剂是硬脂酸、微粉硅胶、胶态二氧化硅中任意一种或一种以上。
进一步的,所述PH调节剂是pKa低于5的有机酸或无机酸。
进一步的,所述PH调节剂选自谷氨酸、天冬氨酸、抗坏血酸、叶酸、柠檬酸、延胡索酸、枸橼酸、苹果酸、酒石酸、抗坏血酸、以及所述各种酸的盐形式可以中的一种或一种以上。
进一步的,所述填充剂是微晶纤维素、乳糖、蔗糖、赤藓糖醇、甘露醇中的一种或一种以上。
本发明还提供了制备上述组合物的方法,采用湿法介质研磨方法制备所述组合物,步骤包括:将原材料混合液加入到介质研磨机中进行研磨,出料,得到纳米混悬液,再经制粒即可。
进一步的,研磨的温度为2-8℃,当研磨至原材料的粒径范围D90<1000nm时停止。
进一步的,制粒采用流化床制粒、喷雾干燥制粒或冷冻干燥制粒。
综上,本发明采用上述技术方案,所具有的有益效果包括:本发明筛选出的成分配合湿法研磨方法,得到的药物组合物,改善了药物的口服生物利用度;该组合物可在常温下保持稳定,可显著降低药品的储存和流通成本;采用本发明制备出的颗粒可进一步制得药物颗粒剂、胶囊剂、片剂等药物剂型,制备方法简单、成本适宜,适用于工业化大规模生产。
附图说明
图1为尼替西农案例处方在pH 6.8磷酸盐介质溶出曲线测定(n=6)。
具体实施方式
下面通过具体的实施例对本发明做进一步的详细描述。
实施例一:本发明提供的一种含有尼替西农的药物,成分见下表:
处方组成 | 所占质量百分比 |
尼替西农 | 10% |
羟丙基纤维E-15LV | 3% |
柠檬酸 | 5% |
十二烷基硫酸钠 | 2% |
蔗糖 | 70% |
草莓香精 | 余量为矫味剂 |
胶态二氧化硅 | 1% |
a、将处方量的羟丙基纤维素分多次缓慢撒入纯化水中,边加边搅拌至完全溶解;
b、向羟丙基纤维素溶液中缓慢加入尼替西农,搅拌均匀;
c、将上述混合液加入到介质研磨机中进行预研磨30min,再向研磨介质中加入十二烷基硫酸钠继续碾磨3h,控制研磨机温度2-8℃,当碾磨至原料药粒径范围D90<300nm,出料,得到纳米混悬液。
d、将蔗糖用流化床预热至40℃,将得到的纳米混悬液作为喷液,喷入流化床中制粒。
e、将制得的颗粒和胶态二氧化硅经1.0mm筛网进行整粒。
f、最后向整粒后的颗粒中加入草莓香精,放入总混桶,以混合速度20rpm混合10min,即得最终颗粒。
实施例二:本发明提供的一种含有尼替西农的药物,成分见下表:
表2:药用组合物处方2
处方组成 | 原材料所占质量百分比 |
尼替西农 | 10% |
泊洛沙姆188 | 3% |
柠檬酸 | 5% |
十二烷基硫酸钠 | 2% |
蔗糖 | 70% |
草莓香精 | 余量为矫味剂 |
胶态二氧化硅 | 1% |
a、将处方量的泊洛沙姆188缓慢撒入纯化水中,边加边搅拌至完全分散完全。
b、向泊洛沙姆溶液中缓慢加入柠檬酸和尼替西农,搅拌均匀。
c、将上述混合液加入到介质研磨机中进行预研磨30min,再向研磨介质中加入十二烷基硫酸钠继续碾磨3h,控制研磨机温度2-8℃,当碾磨至原料药粒径范围D90<300nm,出料,得到纳米混悬液。
d、将蔗糖用流化床预热至40℃,将得到的纳米混悬液作为喷液,喷入流化床中制粒。
e、将制得的颗粒和胶态二氧化硅经1.0mm筛网进行整粒。
f、最后向整粒后的颗粒中加入草莓香精,放入总混桶,以混合速度20rpm混合10min,即得最终颗粒。
需要说明的是,在成分的选择上,表面稳定剂还可以选择羟丙甲基纤维素、聚乙烯吡咯烷酮、环氧乙烷和环氧丙烷的嵌段共聚物、磺基琥珀酸二辛酯钠、聚乙二醇维生素E琥珀酸酯;助流剂还可以选择硬脂酸、微粉硅胶;所述PH调节剂还可以选择谷氨酸、天冬氨酸、抗坏血酸、叶酸、延胡索酸、枸橼酸、苹果酸、酒石酸、抗坏血酸、以及所述各种酸的盐形式,所述填充剂还可以选择微晶纤维素、乳糖、赤藓糖醇、甘露醇,,在采用各成分的量的选择,尼替西农选择的量在0.1%-10%,表面稳定剂0.1%-5%,助流剂0%-1%,PH调节剂0%-5%,填充剂70-95%,制粒方法还可以采用喷雾干燥制粒或冷冻干燥制粒,同样能够制得具有相同效果的药物,为了节省篇幅,仅以实施例一至实施例二作为举例,不再逐一进行赘述。
采用现有技术方法对实施例一、二,以及现有技术药物组合物(如表3中的药用组合物处方3)进行性能检测的对比:
表3:药用组合物处方3
处方组成 | 每片含量(mg) |
尼替西农 | 5.00 |
预胶化淀粉 | 95.00 |
总重 | 100.00 |
制备方法:
a、将处方量的尼替西农和预胶化淀粉混合均匀。
b、将上述混合物罐装至羟丙甲基纤维素胶囊。
表4:5mg规格加速试验(40℃/75%RH)检测结果
备注:处方一、二为改良处方,处方三为阴性对照处方。
Oxo:氧代四氢呫吨酮,尼替西农增长最显著的杂质。
体外释药性能的研究:取处方一、二、三样品进行pH 6.8磷酸盐介质中溶出测定。溶出测定方法:浆法,转速50rpm,介质体积900ml,取样时间点10min、15min、20min、30min、45min、60min,根据测定结果绘制释药浓度-时间曲线如下所示。
结果:如图1所示,处方一、二的药物组合物具有与处方三(原研胶囊剂处方作为对照)相比具有更高的溶出速率,因此可能具有良好的口服生物利用度;同时处方一、二药物组合物在加速条件下较处方三杂质增长较缓慢,为药品能在常温下保持稳定提供了依据。综上所述,改良后的制剂其溶出速率大幅提高,稳定性得到改善,与预期目标一致。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种含有尼替西农的药物组合物,其特征在于,该组合物包括尼替西农、表面稳定剂、助流剂、PH调节剂、以及填充剂,各原材料占组合物的重量百分比分别为:尼替西农0.1%-10%,表面稳定剂0.1%-5%,助流剂0%-1%,PH调节剂0%-5%,填充剂70-95%。
2.根据权利要求1所述的组合物,其特征在于,表面稳定剂是羟丙基纤维素、羟丙甲基纤维素、聚乙烯吡咯烷酮、环氧乙烷和环氧丙烷的嵌段共聚物、磺基琥珀酸二辛酯钠、十二烷基硫酸钠、泊洛沙姆、聚乙二醇维生素E琥珀酸酯的一种或一种以上。
3.根据权利要求1所述的组合物,其特征在于,所述助流剂是硬脂酸、微粉硅胶、胶态二氧化硅中任意一种或一种以上。
4.根据权利要求1所述的组合物,其特征在于,所述PH调节剂是pKa低于5的有机酸或无机酸。
5.根据权利要求4所述的组合物,其特征在于,所述PH调节剂选自谷氨酸、天冬氨酸、抗坏血酸、叶酸、柠檬酸、延胡索酸、枸橼酸、苹果酸、酒石酸、抗坏血酸、以及所述各种酸的盐形式可以中的一种或一种以上。
6.根据权利要求1所述的组合物,其特征在于,所述填充剂是微晶纤维素、乳糖、蔗糖、赤藓糖醇、甘露醇中的一种或一种以上。
7.一种制备权利要求1-6任意一项所述组合物的方法,其特征在于,采用湿法介质研磨方法制备所述组合物,步骤包括:将原材料混合液加入到介质研磨机中进行研磨,出料,得到纳米混悬液,再经制粒即可。
8.根据权利要求7所述的制备方法,其特征在于,研磨的温度为2-8℃,当研磨至原材料的粒径范围D90<1000nm时停止。
9.根据权利要求7所述的制备方法,其特征在于,制粒采用流化床制粒、喷雾干燥制粒或冷冻干燥制粒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011193048.0A CN112107548A (zh) | 2020-10-30 | 2020-10-30 | 一种含有尼替西农的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011193048.0A CN112107548A (zh) | 2020-10-30 | 2020-10-30 | 一种含有尼替西农的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112107548A true CN112107548A (zh) | 2020-12-22 |
Family
ID=73794094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011193048.0A Pending CN112107548A (zh) | 2020-10-30 | 2020-10-30 | 一种含有尼替西农的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112107548A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102976948A (zh) * | 2012-11-28 | 2013-03-20 | 郑州大明药物科技有限公司 | 尼替西农的制备方法 |
WO2013181292A1 (en) * | 2012-05-29 | 2013-12-05 | Biotie Therapies, Inc. | Nitisinone formulations |
CN103747781A (zh) * | 2011-06-23 | 2014-04-23 | 瑞典奥芬拜欧沃特姆国际公司 | 含有尼替西农的液体药物组合物 |
CN108495623A (zh) * | 2016-02-11 | 2018-09-04 | 迪法玛公司 | 含有2-(2-硝基-4-三氟甲基-苯甲酰基)-1,3-环己二酮的稳定固体药物配制品 |
-
2020
- 2020-10-30 CN CN202011193048.0A patent/CN112107548A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103747781A (zh) * | 2011-06-23 | 2014-04-23 | 瑞典奥芬拜欧沃特姆国际公司 | 含有尼替西农的液体药物组合物 |
WO2013181292A1 (en) * | 2012-05-29 | 2013-12-05 | Biotie Therapies, Inc. | Nitisinone formulations |
CN102976948A (zh) * | 2012-11-28 | 2013-03-20 | 郑州大明药物科技有限公司 | 尼替西农的制备方法 |
CN108495623A (zh) * | 2016-02-11 | 2018-09-04 | 迪法玛公司 | 含有2-(2-硝基-4-三氟甲基-苯甲酰基)-1,3-环己二酮的稳定固体药物配制品 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105007897B (zh) | 含有无定形托伐普坦的口服施用的混悬剂 | |
CN102805733A (zh) | 颗粒制剂及其制造方法 | |
KR20140095500A (ko) | 제약 제제 | |
CN104116741B (zh) | 盐酸维拉佐酮组合物及其制备方法 | |
US20210251909A1 (en) | Taste masking drug formulations | |
CN109394685B (zh) | 一种vegfr抑制剂的药物组合物及其制备方法 | |
WO2022166701A1 (zh) | 一种组合物及其制备方法 | |
CA3169671A1 (en) | Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate | |
CN102908305B (zh) | 一种含有盐酸决奈达隆的口服固体药物组合物及其制备方法 | |
CN109793715B (zh) | 一种阿哌沙班口服固体制剂及其制备方法 | |
CN111110646A (zh) | 一种低规格醋酸阿比特龙口服制剂的处方及制备方法 | |
CN112603900A (zh) | 含[(4-羟基-1-甲基-7-苯氧基-异喹啉-3-羰基)-氨基]-乙酸的固体制剂 | |
CN111184693B (zh) | 一种raf激酶抑制剂制剂及其制备方法 | |
CN112107548A (zh) | 一种含有尼替西农的药物组合物及其制备方法 | |
CN114533735A (zh) | 盐酸鲁拉西酮药物组合物及其制备方法 | |
WO2004103346A1 (en) | Pharmaceutical compositions of acitretin | |
CN108159007A (zh) | 一种盐酸普拉克索缓释制剂及其制备方法 | |
CN113476415A (zh) | 一种盐酸鲁拉西酮片剂及其制备方法 | |
US20220395514A1 (en) | Low-dose celecoxib preparation | |
CN107468652A (zh) | 一种固体干混悬温敏凝胶剂及其制备方法 | |
CN111803464A (zh) | 一种塞来昔布胶囊制剂 | |
US20210251902A1 (en) | Delamanid-containing composition | |
EP3275434B1 (en) | An extended release oral dosage form | |
CN108096251B (zh) | 一种吉非替尼药物组合物及其制备方法 | |
WO2019200512A1 (zh) | 一种抗凝剂的速释药物制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201222 |
|
RJ01 | Rejection of invention patent application after publication |